Clinical study of avastin combined with FOLFOX4 in the treatment of advanced metastatic colorectal cancer
10.13699/j.cnki.1001-6821.2015.05.008
- VernacularTitle:贝伐珠单抗联合 FOLFOX4化疗方案治疗晚期转移性结直肠癌的临床研究
- Author:
Qin ZHANG
1
;
You-Cai ZHU
;
Jin BAO
;
Yong-Ping XU
;
Gang CHEN
Author Information
1. 武警浙江总队嘉兴医院 肿瘤科
- Keywords:
metastasis colorectal cancer;
avastin;
FOLFOX4;
clinical efficacy;
adverse reaction
- From:
The Chinese Journal of Clinical Pharmacology
2015;(5):345-347
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of avastin combined with oxaliplatin ( L-OHP ) +5 -fluorouracil ( 5 -FU ) +leucovorin ( LV ) ( FOLFOX4 ) on the treatment of advanced metastatic colorectal cancer( MCC).Methods Eighty four patients with MCC were recruited from April 2011 to December 2013 in our hospital.Of the included 84 cases, 39 patients received avastin plus FOLFOX4 regimen and other 45 cases received FOLFOX4 chemotherapy only.FOLFOX4 regimen:L-OHP 85 mg · m -2 by travenous drip in 2 hours on day 1 and LV 200 mg· m -2 by intravenous drip in 2 hours on day 1 and 2, 5-FU 400 mg· m-2 by intravenous injection on day 1 and 2 and 5-FU 600 mg · m-2 by intravenous drip on day 1 and 2.Avastin regimen:avastin 10 mg· kg -1 +0.9%NaCl injection 100 mL by intravenous drip in 1 hour ( 90 min for the first time ) , once two weeks.After two cycles treatment, the data of objective response rate(ORR)and chemotherapy related adverse reactions were compared between the two groups.Results The ORR and disease control rate ( DCR ) in avastin +FOLFOX4 group were much higher than those in FOLFOX4 group ( P<0.05 ).But the chemotherapy related adverse reactions were not statistically different between the two groups ( P >0.05 ).Conclusion FOLFOX4 chemotherapy regimen combined with avastin can significantly increase the clinical efficacy on patients with MCC, without increasing adverse reactions.
